Bausch & Lomb drops Opcon-A comparative ad claims after Ciba NAD challenge.
This article was originally published in The Tan Sheet
Executive Summary
BAUSCH & LOMB DISCONTINUES CERTAIN OPCON-A EYE DROP ADS following a written agreement with Ciba Vision, which manufactures Vasocon-A eye drops. According to a recent case report issued by the National Advertising Division of the Council of Better Business Bureaus, Ciba took issue with print and television ads for Bausch & Lomb's Opcon-A that claimed that Opcon-A is "the only eye drop that relieves both redness and itching" and that "no other eye drop calms and clears your eyes like new Opcon-A." Ciba filed a complaint with NAD about the Bausch & Lomb claims.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: